All In Biotech

Free tool

FAERS Monitor: Phospholine Iodide

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 011963 or its brand name (Phospholine Iodide, Echothiophate Iodide). Reports on generic versions are filed under their own applications.

Reports

147

Serious

75

51% of reports

Hospitalization

6

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • intraocular pressure increased27
  • drug ineffective22
  • visual impairment17
  • eye pain13
  • visual acuity reduced10
  • blindness9
  • blindness unilateral8
  • ocular hyperaemia8
  • eye disorder7
  • eye irritation7
  • vision blurred7
  • glaucoma6
  • headache6
  • product quality issue6
  • malaise5

Reports by year received

View as table
YearReports
20041
20075
20084
20091
20109
20119
20129
201311
201420
20159
20166
20177
20184
20198
202025
202110
20223
20233
20242
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,012 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intraocular pressure increasedSignal27302.9215.37,814
blindness unilateralSignal881.241.4556
glaucomaSignal644.620.4214
visual acuity reducedSignal1043.123.7371
eye painSignal1333.019.6373
blindnessSignal931.616.8237
eye disorderSignal730.514.8171
ocular hyperaemiaSignal824.112.3155
visual impairmentSignal1719.612.6284
eye irritationSignal717.48.493
vision blurredSignal77.33.532
product quality issueSignal66.32.922
drug ineffectiveSignal222.41.617
malaise51.60.71
headache61.40.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.